Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewConivaptan hydrochloride is a very high affinity vasopressin V1A and V2 antagonist (Ki values are 0.61 and 0.66 - 3.04 nM, respectively). Inhibits vasopressin-induced pressor responses in rats without altering blood pressure, and increases urine flow while decreasing urine osmolality. Orally bioavailable.
Conivaptan hydrochloride is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
| 分子量 | 535.04 |
| 公式 | C32H26N4O2.HCl |
| 储存 | Desiccate at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 168626-94-6 |
| PubChem ID | 151171 |
| InChI Key | IKENVDNFQMCRTR-UHFFFAOYSA-N |
| Smiles | CC1=NC2=C(C3=CC=CC=C3N(C(C4=CC=C(C=C4)NC(C5=C(C6=CC=CC=C6)C=CC=C5)=O)=O)CC2)N1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Tahara et al (1997) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J.Pharmacol.Exp.Ther. 282 301 PMID: 9223568
Yatsu et al (1997) Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. Eur.J.Pharmacol. 321 225 PMID: 9063692
关键词: Conivaptan hydrochloride, Conivaptan hydrochloride supplier, conivaptan, HCl, very, high, affinity, vasopressin, V1A, V2, antagonists, antagonism, AVP, orally, bioavailable, Vasopressin, Receptors, 6830, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Conivaptan hydrochloride and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.